Hepatitis B – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Hepatitis B Market Outlook

Thelansis’s “Hepatitis B Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hepatitis B treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Hepatitis B Overview

Hepatitis B is primarily transmitted via contact with infected blood or certain bodily fluids. Common transmission routes include perinatal transfer from an infected mother to her newborn during childbirth, unsterile medical or dental equipment, unprotected sex, unsterile needles, and sharing personal items such as razors, toothbrushes, and nail clippers. Hepatitis B is often termed a “silent epidemic” as most individuals are asymptomatic during acute or chronic infection, leading to unintentional viral transmission and ongoing propagation of the virus. Chronic asymptomatic carriers may still experience progressive liver damage, potentially resulting in cirrhosis or liver cancer. The hepatitis B virus (HBV) has a complex replication cycle, entering host liver cells and transforming its DNA into covalently closed circular DNA (cccDNA) within the nucleus. This cccDNA serves as a template for viral replication. Newly formed HBV particles are released from the liver cell while cccDNA persists in the nucleus, where it can integrate into the host genome and continue viral production. The replication process is prone to errors, contributing to the genetic diversity of HBV. The differential diagnosis for hepatitis B includes other hepatitis viruses (A, C, E), alcoholic hepatitis, and autoimmune hepatitis, necessitating thorough clinical evaluation and laboratory testing. Conditions like hemochromatosis, characterized by abdominal tenderness and abnormal liver transaminase levels, should also be considered. Hemochromatosis may present distinctive features like bronze skin discoloration and impaired glucose tolerance. Acute hepatitis B resolves spontaneously in 95% of healthy adults, with most cases requiring only supportive care. Severe acute cases (bilirubin >10 mg/dl, INR >1.6, hepatic encephalopathy) and prolonged severe cases (total bilirubin >3 mg/dl, direct bilirubin >1.5 mg/dl, INR >1.5, hepatic encephalopathy, ascites) warrant antiviral therapy. FDA-approved treatments for chronic hepatitis B include interferons (peginterferon alfa-2a, interferon alfa-2b), nucleoside analogs (entecavir, lamivudine, telbivudine), and nucleotide analogs (adefovir, tenofovir), with entecavir and tenofovir preferred for their higher resistance barrier in acute infections.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: